Strong synergy with APR-246 and DNA-damaging drugs in primary cancer cells from patients with TP53 mutant High-Grade Serous ovarian cancer - Wikidata - wikimedia - TriplyDB

Strong synergy with APR-246 and DNA-damaging drugs in primary cancer cells from patients with TP53 mutant High-Grade Serous ovarian cancer

Strong synergy with APR-246 and DNA-damaging drugs in primary cancer cells from patients with TP53 mutant High-Grade Serous ovarian cancer

http://www.wikidata.org/entity/Q36904012

about

Molecular Mechanisms of p53 Deregulation in Cancer: An Overview in Multiple Myeloma The Potential of Targeting Ribosome Biogenesis in High-Grade Serous Ovarian Cancer.Reviving the guardian of the genome: Small molecule activators of p53.Molecularly targeted therapies for p53-mutant cancers.PRIMA-1 and PRIMA-1Met (APR-246): From Mutant/Wild Type p53 Reactivation to Unexpected Mechanisms Underlying Their Potent Anti-Tumor Effect in Combinatorial Therapies.The small molecule SI113 synergizes with mitotic spindle poisons in arresting the growth of human glioblastoma multiforme.Mutant p53R270H drives altered metabolism and increased invasion in pancreatic ductal adenocarcinoma.Hypoxia-Induced Cisplatin Resistance in Non-Small Cell Lung Cancer Cells Is Mediated by HIF-1α and Mutant p53 and Can Be Overcome by Induction of Oxidative Stress.High expression of the p53 isoform γ is associated with reduced progression-free survival in uterine serous carcinoma.

P2860

Q28074490-5BC8B80A-D0BC-4152-9749-C00EAE507B89 Q37631697-9B5A38D0-CE24-4C7D-B43E-61C498D6A6E4 Q39205536-9269E3B2-9918-4EFA-B84D-B56022708926 Q39393193-3420EB3A-0110-442F-9107-34DF81BE26B6 Q47274927-6D6EE660-4DE1-4DED-A3C6-A6221FADCD95 Q47861000-38C75BFF-1BAF-4673-B01A-72D0E2FED5D0 Q49788157-D468B5F4-597B-44FA-B4BA-1068E5360CA7 Q53691994-261B6BCC-8413-4DCB-91D2-07068516754C Q55452619-1C87CCFC-D92A-4323-8B34-4782362CEB4C

P2860

Strong synergy with APR-246 and DNA-damaging drugs in primary cancer cells from patients with TP53 mutant High-Grade Serous ovarian cancer

http://www.wikidata.org/entity/Q36904012

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Strong synergy with APR-246 an ...... gh-Grade Serous ovarian cancer

@en

type

label

Strong synergy with APR-246 an ...... gh-Grade Serous ovarian cancer

@en

prefLabel

Strong synergy with APR-246 an ...... gh-Grade Serous ovarian cancer

@en

P1433

Q36904012-CD0A2C89-C153-4C26-ABC6-53B61E03F9FA

P1476

Q36904012-AB0AF8DF-6A00-4092-8F90-549CFEFA2125

P2093

Q36904012-2CE028C8-6512-4F20-ADCB-E2EABD96E1AC

Q36904012-B446AA3C-D5BC-4CB0-BD60-D4978687A3AD

Q36904012-C9D6DC94-623B-421B-B3AA-4ECE874B17B7

Q36904012-DE824676-7640-41FD-86E6-A9B56139CDDC

Q36904012-E88AFA56-1C1B-4003-9C07-9D0E9218AA39

P2860

Q36904012-043E5635-CF35-431F-B27C-779B52A51142

Q36904012-134023C9-2C32-4312-82E8-1F580E1A84DB

Q36904012-16A488DC-CE3B-489F-BCCC-09FFB2531726

Q36904012-18E098BF-DCD5-4457-BA0E-47BF56B675C6

Q36904012-256CA412-C3DB-4BDA-B51B-2F783EBD5A03

Q36904012-257BEB3B-0768-472D-9AFB-97477B5E745E

Q36904012-38FB2EC0-757E-40B1-8C2A-9B88814D6AE0

Q36904012-41664579-C10D-4160-AF02-017F18549682

Q36904012-4AA63207-1DCE-4180-8CF1-F09ECC123444

Q36904012-5114AE7E-F7C5-4B34-8A74-3F5A460516D7

P2888

Q36904012-D7F86F8F-66E9-4162-B835-7DDAFFAAD212

P304

Q36904012-B7A732C7-0BC4-4E77-B9AC-1CC0A6B602F4

P31

Q36904012-B90ACF3A-A637-4615-BE04-CA6C97E19208

P356

Q36904012-5414A417-3105-4DE2-B4BB-30A05E3F5A16

P433

Q36904012-AF0D125B-75E9-41EE-9CFC-42F1B90C8269

P478

Q36904012-FE011BBF-336E-429F-8DFF-763AD4488799

P50

Q36904012-CC5D351C-F72C-4E70-9097-26F9B7E31C8C

P577

Q36904012-7C3A4D92-EE38-43AC-A65A-AD9B93C7BCB5

P6179

Q36904012-404E08A7-FB46-4401-9FF3-7EFBE35C5C05

P698

Q36904012-39598AE5-67CF-495A-8146-693E9F40F567

P921

Q36904012-00964CF4-D3B0-4E71-B555-3FE099FD1005

P932

Q36904012-93BA18C0-7EC5-4505-A394-5EEA452DD0C1

P356

S13048-016-0239-6

P1433

Journal of Ovarian Research

P1476

Strong synergy with APR-246 an ...... gh-Grade Serous ovarian cancer

@en

P2093

Daria Glaessgen

http://www.w3.org/2001/XMLSchema#string

Jessica Alfredsson

http://www.w3.org/2001/XMLSchema#string

Nina Mohell

http://www.w3.org/2001/XMLSchema#string

Svetlana Bajalica-Lagercrantz

http://www.w3.org/2001/XMLSchema#string

Åsa Fransson

http://www.w3.org/2001/XMLSchema#string

P2860

Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer

Pharmacotherapy for recurrent ovarian cancer: current status and future perspectives

DNA topoisomerases and their poisoning by anticancer and antibacterial drugs

Blinded by the Light: The Growing Complexity of p53

Cisplatin: mode of cytotoxic action and molecular basis of resistance

Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction

Predicting survival in head and neck squamous cell carcinoma from TP53 mutation.

Survival of patients with structurally-grouped TP53 mutations in ovarian and breast cancers

Multicellular resistance: a paradigm for clinical resistance?

Ovarian cancer development and metastasis.

P2888

s13048-016-0239-6

P304

27

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S13048-016-0239-6

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P50

P577

2016-05-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1014391009

http://www.w3.org/2001/XMLSchema#string

P698

27179933

http://www.w3.org/2001/XMLSchema#string

P921

P932

4868029

http://www.w3.org/2001/XMLSchema#string